ライフサイエンスコーパス: digital rectal examination

1 r, palpable resistance and pain/blood during digital rectal examination.

2 g/mL; there was still no palpable disease on digital rectal examination.

3 ed GITT and palpable stools in the rectum at digital rectal examination.

4 testing for prostate-specific antigen and a digital rectal examination.

5 pliance were 85% for PSA testing and 86% for digital rectal examination.

6 or PSA testing and ranged from 41 to 46% for digital rectal examination.

7 o and had an annual measurement of PSA and a digital rectal examination.

8 d longitudinal prostate-specific antigen and digital rectal examination.

9 of routine screening or of stool obtained by digital rectal examination.

10 els despite normal PSA levels and results of digital rectal examination.

11 tions of periodic PSA testing (all cohorts), digital rectal examination (14 cohorts), and rebiopsy (1

12 est that for men with no cancer suspected on digital rectal examination, a PSA level of 4.0 to 5.0 ng

13 2 men 55 years of age or older with a normal digital rectal examination and a prostate-specific antig

14 aximum response to AD as assessed by monthly digital rectal examination and prostate-specific antigen

15 the acceptable operating characteristics of digital rectal examination and prostate-specific antigen

16 s of early detection of prostate cancer with digital rectal examination and prostate-specific antigen

17 ate cancer-screening programs and had normal digital rectal examination and PSA levels (<4 ng/ml).

18 These data suggest that (1) digital rectal examination and PSA levels are insensitiv

19 The positive predictive value of combined digital rectal examination and PSA measurement has been

20 vorable set of assumptions is used, one-time digital rectal examination and PSA measurement may incre

21 A cost-effectiveness model for one-time digital rectal examination and PSA measurement was const

22 Likelihood ratios for digital rectal examination and PSA measurement were esti

23 Digital rectal examination and urinalysis should be perf

24 ostate-specific antigen level or an abnormal digital rectal examination and was offered to all men at

25 lowing abnormal prostate-specific antigen or digital rectal examination) and 669 detected not for cau

26 rial prostate-specific antigen measurements, digital rectal examinations, and biopsies, with treatmen

27 d include prostate-specific antigen testing, digital rectal examinations, and serial prostate biopsie

28 nd prostate-specific antigen measurement and digital rectal examination at 3-month intervals).

29 However, digital rectal examination detects cancer that would oth

30 formed in two steps, initially using PSA and digital rectal examination (DRE) alone and subsequently

31 ted prostate needle biopsy due to suspicious digital rectal examination (DRE) findings and/or PSA lev

32 rative combined-modality therapy (CMT) using digital rectal examination (DRE) has been proposed as a

33 strecurrence PSA doubling time, and positive digital rectal examination (DRE) of the prostatic fossa

34 tive study included 118 patients with normal digital rectal examination (DRE) results but elevated pr

35 were asymptomatic, but 33 had heme-positive digital rectal examination (DRE) results or hematochezia

36 We defined serendipity in digital rectal examination (DRE) screening as the discov

37 ific antigen (PSA) concentration, PSA slope, digital rectal examination, dysplastic glands or prostat

38 ry, men were followed up with PSA assays and digital rectal examinations every 3 months for the first

39 such as prostate-specific antigen levels and digital rectal examination findings, were correlated wit

40 sists of serum prostate-specific antigen and digital rectal examination, followed by transrectal ultr

41 e offered annual PSA testing for 6 years and digital rectal examination for 4 years.

42 ay be more sensitive than sextant biopsy and digital rectal examination for sextant localization of c

43 re than 4.0 ng per milliliter or an abnormal digital rectal examination, had a final PSA determinatio

44 On digital rectal examination, his prostate was moderately

45 age, race/ethnicity, prior biopsy, PSA, and digital rectal examination) improved the stratification

46 US is more sensitive but less specific than digital rectal examination in the detection of local rec

47 nsitivity and specificity of sextant biopsy, digital rectal examination, MR imaging, and MR spectrosc

48 Sextant biopsy, digital rectal examination, MR imaging, MR spectroscopy,

49 ecific antigen (PSA) of 4.0 ng/mL or less, a digital rectal examination not suspicious for prostate c

50 ific antigen level of 4 ng/mL or less, and a digital rectal examination not suspicious for prostate c

51 The tumor was palpable on digital rectal examination on the anterior wall of rectu

52 prostate-specific-antigen (PSA) testing and digital rectal examination on the rate of death from pro

53 state biopsy because of abnormal findings on digital rectal examination or elevated PSA (> or = 4 ng/

54 antigen levels, usually in combination with digital rectal examination or transrectal prostatic ultr

55 zed by a preceding prostate-specific antigen/digital rectal examination prompt (yes/no) and noncases

56 ed beyond the current clinical parameters of digital rectal examination, prostate-specific antigen, a

57 Rome III constipation criteria, stool diary, digital rectal examination, rectal diameter assessed fro

58 for prostate biopsy on the basis of abnormal digital rectal examination results or elevated prostate-

59 ific antigen (PSA) level, PSA density, race, digital rectal examination results, and biopsy results b

60 prostate-specific antigen (PSA) or abnormal digital rectal examination results, often with prior neg

61 and 0.70 to 0.78 for models without and with digital rectal examination results, respectively (P < .0

62 with transrectal ultrasound (TRUS) findings, digital rectal examination results, serum PSA level, and

63 A digital rectal examination revealed an enlarged prostate

64 erum prostate specific antigen, and abnormal digital rectal examination, serum 25-OH D less than 30 n

65 cer, serum prostate-specific antigen levels, digital rectal examination status, stage, grade, primary

66 A digital rectal examination that is abnormal but not susp

67 ported prostate-specific antigen testing and digital rectal examination (the latter available for >60

68 In patients who have abnormalities on digital rectal examination, the risk for a large intraca

69 By comparing transrectal US and digital rectal examination, the sensitivities were 76% a

70 On digital rectal examination, the tumor is palpated approx

71 sk categories are prostate specific antigen, digital rectal examination, transrectal biopsy and their

72 nts with elevated PSA levels and/or abnormal digital rectal examination underwent transrectal US-guid

73 d a directed history, examination (including digital rectal examination), urinalysis and bladder diar

74 de, exceeded 4.0 ng per milliliter or if the digital rectal examination was abnormal.

75 Digital rectal examination was often not performed but a

76 A digital rectal examination was performed and revealed a

77 Digital rectal examination was performed in only 56.4%.

78 pectively, while sensitivities of biopsy and digital rectal examination were 48% and 16%, respectivel

79 TMPRSS2:ERG (T2:ERG) RNA in the urine after digital rectal examination would improve specificity ove